Pancreatic Cancer

Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer
PharmaCyte Updates Status Of Investigational New Drug Application For Pancreatic Cancer Candidate

Pancreatic Cancer Recent News

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio Inc (NASDAQ: IBRX) has 
|
Why Did HCW Biologics Shares More Than Double Today?
|
Why Are Rafael Shares Plunging Today?
|
See Why RenovoRx Stock Is Shooting Higher On Tuesday
|
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
|
Why XOMA Stock Is Trading Higher Wednesday?
|
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
|
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
|
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer
|
Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
|
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
|
Why Surface Oncology Shares Spiked 19% Today
Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday.
|
AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program
|
DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank
|
NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars
Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) 
|
EXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market
|
New Drug Could Transform Pancreatic Cancer Treatment
|
13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved